Form 8-K OTONOMY, INC. For: Aug 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes Needed
August 30, 2017 10:44 AM EDTCowen analyst Ken Cacciatore lowered his price target on Otonomy (NASDAQ: OTIC) to $9.00 (from $55.00) while maintaining an Outperform rating following the Otividex failure.
Cacciatore said said the company will now need to make dramatic and rapid spending reductions and the focus... More
UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX Fails
August 30, 2017 7:33 AM EDT(Updated - August 30, 2017 7:37 AM EDT)
Otonomy (NASDAQ: OTIC) dropped 77% after shares resumed following a brief trading halt pending results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease. The clinical trial missed its primary endpoint.
... MoreOtonomy (OTIC) to Resume Trading at 7:30 AM ET
August 30, 2017 7:25 AM EDTOtonomy (NASDAQ: OTIC) to Resume Trading at 7:30 AM ET
... More